TY - JOUR
T1 - Future research directions in acute lung injury
T2 - Summary of a National Heart, Lung, and Blood Institute Working Group
AU - Matthay, Michael A.
AU - Zimmerman, Guy A.
AU - Esmon, Charles
AU - Bhattacharya, Jahar
AU - Coller, Barry
AU - Doerschuk, Claire M.
AU - Floros, Joanna
AU - Gimbrone, Michael A.
AU - Hoffman, Eric
AU - Hubmayr, Rolf D.
AU - Leppert, Mark
AU - Matalon, Sadis
AU - Munford, Robert
AU - Parsons, Polly
AU - Slutsky, Arthur S.
AU - Tracey, Kevin J.
AU - Ward, Peter
AU - Gail, Dorothy B.
AU - Harabin, Andrea L.
PY - 2003/4/1
Y1 - 2003/4/1
N2 - Acute lung injury (ALI) and its more severe form, the acute respiratory distress syndrome (ARDS), are syndromes of acute respiratory failure that result from acute pulmonary edema and inflammation. The development of ALI/ARDS is associated with several clinical disorders including direct pulmonary injury from pneumonia and aspiration as well as indirect pulmonary injury from trauma, sepsis, and other disorders such as acute pancreatitis and drug overdose. Although mortality from ALI/ARDS has decreased in the last decade, it remains high. Despite two major advances in treatment, low VT ventilation for ALI/ARDS and activated protein C for severe sepsis (the leading cause of ALI/ARDS), additional research is needed to develop specific treatments and improve understanding of the pathogenesis of these syndromes. The NHLBI convened a working group to develop specific recommendations for future ALI/ARDS research. Improved understanding of disease heterogeneity through use of evolving biologic, genomic, and genetic approaches should provide major new insights into pathogenesis of ALI. Cellular and molecular methods combined with animal and clinical studies should lead to further progress in the detection and treatment of this complex disease.
AB - Acute lung injury (ALI) and its more severe form, the acute respiratory distress syndrome (ARDS), are syndromes of acute respiratory failure that result from acute pulmonary edema and inflammation. The development of ALI/ARDS is associated with several clinical disorders including direct pulmonary injury from pneumonia and aspiration as well as indirect pulmonary injury from trauma, sepsis, and other disorders such as acute pancreatitis and drug overdose. Although mortality from ALI/ARDS has decreased in the last decade, it remains high. Despite two major advances in treatment, low VT ventilation for ALI/ARDS and activated protein C for severe sepsis (the leading cause of ALI/ARDS), additional research is needed to develop specific treatments and improve understanding of the pathogenesis of these syndromes. The NHLBI convened a working group to develop specific recommendations for future ALI/ARDS research. Improved understanding of disease heterogeneity through use of evolving biologic, genomic, and genetic approaches should provide major new insights into pathogenesis of ALI. Cellular and molecular methods combined with animal and clinical studies should lead to further progress in the detection and treatment of this complex disease.
UR - http://www.scopus.com/inward/record.url?scp=0345701397&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0345701397&partnerID=8YFLogxK
U2 - 10.1164/rccm.200208-966WS
DO - 10.1164/rccm.200208-966WS
M3 - Article
C2 - 12663342
AN - SCOPUS:0345701397
SN - 1073-449X
VL - 167
SP - 1027
EP - 1035
JO - American journal of respiratory and critical care medicine
JF - American journal of respiratory and critical care medicine
IS - 7
ER -